SOL-GEL TECHNOLOGIES LTD (SLGL)
IL0011417206 - Common Stock
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Top movers analysis one hour before the close of the markets on 2024-12-24: top gainers and losers in today's session.
These stocks are moving in today's session
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.
Curious about the stocks that are showing activity before the opening bell on Tuesday?
Top movers in Monday's after hours session
Monday's after hours session: top gainers and losers
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement ...
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates...
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel reports Second Quarter 2024 Financial Results and provides Corporate Updates...
SLGL Stock Earnings: Sol-Gel Technologies Beats EPS, Beats Revenue for Q2 2024
SLGL stock results show that Sol-Gel Technologies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
SLGL Stock Earnings: Sol-Gel Technologies Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sol-Gel Technologies (NASDAQ:SLGL) just reported results for the second quarter...
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel reports Second Quarter 2024 Financial Results and provides Corporate Updates...
Sol-Gel Technologies Announces Management Realignment
Sol-Gel Technologies Announces Management Realignment...
SLGL Stock Earnings: Sol-Gel Technologies Misses EPS, Misses Revenue for Q1 2024
SLGL stock results show that Sol-Gel Technologies missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
SLGL Stock Earnings: Sol-Gel Technologies Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sol-Gel Technologies (NASDAQ:SLGL) just reported results for the first quarter ...
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates...
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel...
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream...
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
Sol-Gel Reports Full Year 2023 Financial Results and Corporate Developments...
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
SGT-610 has “Orphan Drug” designation status in the U.S. and E.U. and “Breakthrough Therapy” designation status in the U.S., as potentially the first and...
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease...
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Gorlin Syndrome KOL event to be...
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Sol-Gel’s recently...
Israel's Sol-Gel signs Canadian licensing deal for Twyneo, Eposolay (SLGL)
Israel's Sol-Gel (SLGL) has signed an exclusive licensing deal with Searchlight Pharma for the Canadian commercialization rights to its dermatology products Twyneo and Eposolay.
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
Sol-Gel to receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined, plus additional royalties ranging...
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to...
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology...
7 Biotech Stocks That Could Be the Next Big Thing
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.
Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy...
The Top 7 Penny Stocks to Invest in for the Long-Term
Although penny stocks represent extremely high risks, a select few ideas could make for enticing long-term propositions.
Sol-Gel to acquire rare disorder drug patidegib for $4.7M upfront; plans $22.8M offerings
Sol-Gel Technologies (SLGL) said it acquired topically-applied patidegib from PellePharm, and separately announced $22.8M registered direct and private placement offerings.Sol-Gel will...
Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with...
Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in...